IPROOV
29.7.2021 06:03:04 CEST | Business Wire | Press release
iProov , world leader in secure biometric authentication technology, today announced record-breaking growth in the first half of 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728006091/en/
From January to June 2021, iProov saw a 15x increase in the number of people verified using its technology versus the same time period last year. Its flagship Genuine Presence Assurance technology solidified its global market leadership, with verifications growing at a consistent rate of 25% per month worldwide.
This has been driven by demand from organizations needing to verify the identity of online users to prevent fraud. iProov’s patented technology assures the genuine presence of an online user to ensure they are the right person, a real person, and authenticating right now.
iProov has been profitable in 2021, while at the same time growing its worldwide team by 25% to 85 staff. In April, the company welcomed cybersecurity veteran Paul King who joined iProov’s advisory board following 27 years at Cisco, most recently as Chief Security Officer. iProov has also been awarded numerous prestigious awards, including Best Biometric Solution at the 2021 Cyber Security Global Excellence Awards.
In what has been a tumultuous year across the globe, iProov’s technology has provided safe and secure digital identity verification for a growing range of vital services. Since the start of 2021, iProov has added major customers and partners to its portfolio spanning government, health, travel, financial services and ID providers.
In February iProov announced it had been selected by the Australian government to provide the liveness solution for myGovID. Millions of Australians will be able to strengthen their digital identity using a simple face scan on their mobiles, providing access to a range of government services, including online tax.
iProov’s existing service to NHS Digital in the UK became even more crucial this year. Since 2020, iProov has enabled users in England to create an NHS login remotely and securely. A user scans their identity document, such as a valid passport or driver’s license, and then completes a brief iProov face verification to confirm their identity, giving them secure access to the services of the NHS App. Since May 2021, this has included the COVID vaccination status service.
In January 2021, iProov announced a collaboration with its partner, Mvine, to trial private COVID status certificates. The solution enables an individual to register a test result or vaccination status and then securely share that status without disclosing their identity, using either paper or a smartphone. The trials, which took place in care and education settings, were backed by investment from Innovate UK and showcased how biometric verification could greatly simplify the checking of COVID status credentials while enhancing user privacy.
The iProov partner program grew by a third in the first six months of the year, from sectors including identity, health, travel and cryptocurrency. In April, Jumio, the leading provider of AI-powered end-to-end identity verification and eKYC solutions, announced that it had selected iProov technology to deliver high conversion rates, fast onboarding, a natural user experience and small SDK size to its customers.
Andrew Bud, iProov Founder and CEO, commented: “In the first half of 2021, iProov has secured users’ identities online and protected major organizations from fraud on a vast scale across the globe. The dramatic acceleration in the digital identity market, caused by the pandemic, has demonstrated our market leadership based on our unrivaled usability, inclusiveness and resilient security, and the extraordinary scalability of our platform. I am continually impressed by the remarkable work of the iProov team in successfully rising to the many challenges created by such transformative growth.”
The highlights from 2021 so far include: -
Awards
● iProov Takes Home Gold in Three Cybersecurity Excellence Awards: Government, Financial Services, and Identity Proofing & Corroboration - https://www.iproov.com/blog/cyber-security-awards-government-finance
● iProov wins Best Biometric Solution at 2021 Cyber Security Global Excellence Awards - https://www.iproov.com/blog/best-biometric-solution-cyber-security-2021
● iProov Named Winner of Coveted Global InfoSec Award During RSA Conference - https://www.iproov.com/press/iproov-winner-of-global-infosec-award-during-rsa-conference-2021
Customers and partners
● Australian Taxation Office extends national digital identity program with face verification technology from iProov - https://www.iproov.com/press/australian-taxation-office-national-digital-identity-program-face-verification-technology
● Jumio adds iProov’s award winning liveness detection to its KYC platform - https://www.iproov.com/press/jumio-adds-iproov-award-winning-liveness-detection-to-its-kyx-platform
● iProov selected by itsme to support global expansion - https://www.iproov.com/press/iproov-face-verification-selected-by-itsme-to-support-global-expansion
● COVID-19 certificate solution from iProov and Mvine moves into trial phase - https://www.iproov.com/press/uk-covid19-passport-moves-into-trial-phase
Senior team hires
● Cybersecurity veteran Paul King joins iProov’s Advisory Board - https://www.iproov.com/press/cyber-security-veteran-joins-iproov-advisory-board
-ENDS-
About iProov
Founded in 2012, iProov is the world leader in online facial biometric authentication, working with governments, financial institutions and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING and others. iProov’s technologies include Liveness Assurance and Genuine Presence Assurance, which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks that use deepfakes and other synthetic media. Supported by capital from private equity firm JRJ Group, iProov has grown a global footprint with offices in the UK, US and Singapore. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection and as the 5th fastest growing technology company in the UK in the Deloitte 2020 UK Technology Fast 50. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210728006091/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release
The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity
Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release
New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
